Literature DB >> 26157323

microRNA-218 promotes gemcitabine sensitivity in human pancreatic cancer cells by regulating HMGB1 expression.

Zhe Liu1, Ruixia Du1, Jin Long1, Kejian Guo1, Chunlin Ge1, Shulong Bi1, Yuanhong Xu1.   

Abstract

OBJECTIVE: The purpose of this study was to examine the effect of gemcitabine (GEM) on microRNA-218 (miR-218) expression in human pancreatic cancer cells.
METHODS: Quantitative reverse transcription polymerase chain reaction (qRT-PCR) was performed to examine the differences in miR-218 expression between the GEM-sensitive BxPC-3 pancreatic cancer cells and GEM-resistant PANC-1 cells. The effect of GEM on the expression of miR-218 in PANC-1 cells was also investigated. PANC-1 cells were transfected either with HMGB1 siRNA to knock down the expression of HMGB1 or with the recombinant HMGB1 expression vector (pcDNA3.1-HMGB1) to overexpress HMGB1. The effect of ectopic expression of HMGB1 on the apoptosis of miR-218-transfected and GEM-treated PANC-1 cells was examined by flow cytometric analysis.
RESULTS: The miR-218 expression level was lower in GEM-resistant PANC-1 cells compared to GEM-sensitive BxPC-3 cells (P<0.05). The percentage of apoptotic PANC-1 cells was significantly increased in the miR-218 mimic + GEM group compared to the mimic ctrl + GEM group and the normal control group (P<0.01). The HMGB1 expression level was markedly decreased in PANC-1 cells transfected with HMGB1 siRNA but was significantly increased in PANC-1 cells transfected with the recombinant HMGB1 expression vector, pcDNA3.1-HMGB1 (P<0.01). The proportion of apoptotic PANC-1 cells was significantly lower in the miR-218 mimic + GEM + pcDNA3.1-HMGB1 group compared to the miR-218 mimic + GEM + HMGB1 siRNA group (P<0.01).
CONCLUSIONS: The expression level of miR-218 was downregulated in the GEM-resistant cell line. miR-218 promoted the sensitivity of PANC-1 cells to GEM, which was achieved mainly through regulating the expression of HMGB1 in PANC-1 cells.

Entities:  

Keywords:  Pancreatic cancer; apoptosis; gemcitabine (GEM); high mobility group box 1 (HMGB1); microRNA-218 (miR-218)

Year:  2015        PMID: 26157323      PMCID: PMC4490198          DOI: 10.3978/j.issn.1000-9604.2015.04.06

Source DB:  PubMed          Journal:  Chin J Cancer Res        ISSN: 1000-9604            Impact factor:   5.087


  48 in total

Review 1.  Briefing in family characteristics of microRNAs and their applications in cancer research.

Authors:  Qicong Wang; Leyi Wei; Xinjun Guan; Yunfeng Wu; Quan Zou; ZhiLiang Ji
Journal:  Biochim Biophys Acta       Date:  2013-08-14

Review 2.  The functions of HMGB1 depend on molecular localization and post-translational modifications.

Authors:  U Andersson; D J Antoine; K J Tracey
Journal:  J Intern Med       Date:  2014-11       Impact factor: 8.989

Review 3.  The expression of HMGB1 on microparticles released during cell activation and cell death in vitro and in vivo.

Authors:  David S Pisetsky
Journal:  Mol Med       Date:  2014-04-01       Impact factor: 6.354

Review 4.  Pivotal role of microRNAs in cardiac physiology and heart failure.

Authors:  André M Leite-Moreira; André P Lourenço; Inês Falcão-Pires; Adelino F Leite-Moreira
Journal:  Drug Discov Today       Date:  2013-08-13       Impact factor: 7.851

Review 5.  Lentinan reduces tumor progression by enhancing gemcitabine chemotherapy in urothelial bladder cancer.

Authors:  Ming Sun; Wenyan Zhao; Qingpeng Xie; Yunhong Zhan; Bin Wu
Journal:  Surg Oncol       Date:  2014-11-20       Impact factor: 3.279

6.  Chemotherapy (gemcitabine, docetaxel plus gemcitabine, doxorubicin, or trabectedin) in inoperable, locally advanced, recurrent, or metastatic uterine leiomyosarcoma: a clinical practice guideline.

Authors:  A A Gupta; X Yao; S Verma; H Mackay; L Hopkins
Journal:  Curr Oncol       Date:  2013-10       Impact factor: 3.677

7.  KML001 enhances anticancer activity of gemcitabine against pancreatic cancer cells.

Authors:  Moon Hee Yang; Kyu Taek Lee; Sera Yang; Jong Kyoon Lee; Kwang Hyuck Lee; Jong Chul Rhee
Journal:  Anticancer Res       Date:  2015-01       Impact factor: 2.480

8.  A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: the GAMMA trial.

Authors:  C S Fuchs; S Azevedo; T Okusaka; J-L Van Laethem; L R Lipton; H Riess; C Szczylik; M J Moore; M Peeters; G Bodoky; M Ikeda; B Melichar; R Nemecek; S Ohkawa; A Świeboda-Sadlej; S A Tjulandin; E Van Cutsem; R Loberg; V Haddad; J L Gansert; B A Bach; A Carrato
Journal:  Ann Oncol       Date:  2015-01-21       Impact factor: 32.976

9.  Graphene oxide as a chemosensitizer: diverted autophagic flux, enhanced nuclear import, elevated necrosis and improved antitumor effects.

Authors:  Guan-Yu Chen; Chia-Le Meng; Kuan-Chen Lin; Hsing-Yu Tuan; Hong-Jie Yang; Chiu-Ling Chen; Kuei-Chang Li; Chi-Shiun Chiang; Yu-Chen Hu
Journal:  Biomaterials       Date:  2014-11-29       Impact factor: 12.479

10.  MiR-218 impairs tumor growth and increases chemo-sensitivity to cisplatin in cervical cancer.

Authors:  Jiarui Li; Zhang Ping; Hui Ning
Journal:  Int J Mol Sci       Date:  2012-11-28       Impact factor: 5.923

View more
  7 in total

1.  Expression levels and clinical significance of hepsin and HMGB1 proteins in cervical carcinoma.

Authors:  Hui Cheng; Weiqi Wang; Yanling Zhang; Bei Zhang; Jie Cheng; Peng Teng; Xin Tang
Journal:  Oncol Lett       Date:  2017-05-03       Impact factor: 2.967

2.  MiRNA-145 increases therapeutic sensibility to gemcitabine treatment of pancreatic adenocarcinoma cells.

Authors:  Yong Lin; Xin Ge; Yiyang Wen; Zhu-Mei Shi; Qiu-Dan Chen; Min Wang; Ling-Zhi Liu; Bing-Hua Jiang; Yuan Lu
Journal:  Oncotarget       Date:  2016-10-25

3.  HMGB1-mediated autophagy attenuates gemcitabine-induced apoptosis in bladder cancer cells involving JNK and ERK activation.

Authors:  Hubin Yin; Xiaoyu Yang; Wen Gu; Yan Liu; Xinyuan Li; Xiaolong Huang; Xin Zhu; Yong Tao; Xin Gou; Weiyang He
Journal:  Oncotarget       Date:  2017-05-11

4.  The Multifunction Of miR-218-5p-Cx43 Axis In Breast Cancer.

Authors:  Chen Xia; Hong Jiang; Fugui Ye; Zhigang Zhuang
Journal:  Onco Targets Ther       Date:  2019-10-08       Impact factor: 4.345

5.  Identification of Circulating Serum miRNAs as Novel Biomarkers in Pancreatic Cancer Using a Penalized Algorithm.

Authors:  Jaehoon Lee; Hee Seung Lee; Soo Been Park; Chanyang Kim; Kahee Kim; Dawoon E Jung; Si Young Song
Journal:  Int J Mol Sci       Date:  2021-01-20       Impact factor: 5.923

Review 6.  The multifaceted roles of long noncoding RNAs in pancreatic cancer: an update on what we know.

Authors:  Wenjia Zhou; Lu Chen; Chao Li; Rui Huang; Mian Guo; Shangwei Ning; Jingjing Ji; Xiaorong Guo; Ge Lou; Xinqi Jia; Junjie Zhao; Feng Luo; Chunlong Li; Zhaowei Qu; Shan Yu; Sheng Tai
Journal:  Cancer Cell Int       Date:  2020-02-05       Impact factor: 5.722

7.  Upregulation of miR-129-5p increases the sensitivity to Taxol through inhibiting HMGB1-mediated cell autophagy in breast cancer MCF-7 cells.

Authors:  Ying Shi; Weihua Gong; Lu Lu; Yunfeng Wang; Jingjing Ren
Journal:  Braz J Med Biol Res       Date:  2019-10-28       Impact factor: 2.590

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.